What Galderma’s nemolizumab phase II data mean for the competitive biologic landscape in pediatric eczema
Galderma’s nemolizumab phase II data in children aged 2-11 show 52-week itch and lesion relief. Read the analysis.
Novartis expands Cosentyx label to adolescents with hidradenitis suppurativa
FDA approves Novartis Cosentyx for adolescent hidradenitis suppurativa. Discover what this decision means for biologic treatment strategies.
How Arcutis Biotherapeutics’ control of ZORYVE promotion could influence real-world dermatology and pediatric use
Arcutis Biotherapeutics takes full control of ZORYVE promotion. See how this shift could affect real-world dermatology and pediatric prescribing.
Can Alphyn’s multi-target strategy disrupt dermatology? Why Zabalafin’s $25m backing matters
Alphyn Biologics has secured $25 million in a twice-oversubscribed Series B financing round to support its clinical pipeline for dermatologic conditions. The funding will enable the company to advance a global Phase 2b trial of its lead asset, Zabalafin Hydrogel, for atopic dermatitis, while also launching a second Phase 2 program for molluscum contagiosum virus. […]